Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

September 15, 2026

Study Completion Date

October 15, 2026

Conditions
Breast Cancer
Interventions
DRUG

Alpelisib

Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.

DRUG

Fulvestrant

Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).

DRUG

Alpelisib-matching placebo

"Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~After Protocol Amendment 5 is implemented, alpelisib matching-placebo will no longer be supplied or administered once participants have been unblinded."

Trial Locations (68)

1000

Novartis Investigative Site, Brussels

1200

Novartis Investigative Site, Brussels

1303

Novartis Investigative Site, Sofia

3000

Novartis Investigative Site, Leuven

4000

Novartis Investigative Site, Liège

4004

Novartis Investigative Site, Plovdiv

9000

Novartis Investigative Site, Ghent

Novartis Investigative Site, Aalborg

9100

Novartis Investigative Site, Sint-Niklaas

13273

Novartis Investigative Site, Marseille

13353

Novartis Investigative Site, Berlin

15009

Novartis Investigative Site, A Coruña

16132

Novartis Investigative Site, Genova

20089

Novartis Investigative Site, Rozzano

20132

Novartis Investigative Site, Milan

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

23538

Novartis Investigative Site, Lübeck

24127

Novartis Investigative Site, Bergamo

25030

Novartis Investigative Site, Besançon

28040

Novartis Investigative Site, Madrid

28223

Novartis Investigative Site, Pozuelo de Alarcón

29011

Novartis Investigative Site, Málaga

33011

Novartis Investigative Site, Oviedo

33081

Novartis Investigative Site, Aviano

34298

Novartis Investigative Site, Montpellier

35100

Novartis Investigative Site, Padua

40138

Novartis Investigative Site, Bologna

45136

Novartis Investigative Site, Essen

50009

Novartis Investigative Site, Zaragoza

50134

Novartis Investigative Site, Florence

50937

Novartis Investigative Site, Cologne

59300

Novartis Investigative Site, Valenciennes

63011

Novartis Investigative Site, Clermont-Ferrand

69373

Novartis Investigative Site, Lyon

70124

Novartis Investigative Site, Bari

74101

Novartis Investigative Site, Nový Jičín

75475

Novartis Investigative Site, Paris

75970

Novartis Investigative Site, Paris

80131

Novartis Investigative Site, Napoli

83310

Novartis Investigative Site, Bratislava

85925

Novartis Investigative Site, La Roche-sur-Yon

86150

Novartis Investigative Site, Augsburg

90127

Novartis Investigative Site, Palermo

407280

Novartis Investigative Site, Floreşti

T2N 5G2

Novartis Investigative Site, Calgary

K1H 8L6

Novartis Investigative Site, Ottawa

656 53

Novartis Investigative Site, Brno

100 34

Novartis Investigative Site, Prague

128 08

Novartis Investigative Site, Prague

140 59

Novartis Investigative Site, Prague

00029

Novartis Investigative Site, Helsinki

FIN-33521

Novartis Investigative Site, Tampere

115 22

Novartis Investigative Site, Athens

265 04

Novartis Investigative Site, Pátrai

H 1122

Novartis Investigative Site, Budapest

DO4

Novartis Investigative Site, Dublin

00168

Novartis Investigative Site, Roma

05100

Novartis Investigative Site, Terni

85 796

Novartis Investigative Site, Bydgoszcz

3000-075

Novartis Investigative Site, Coimbra

1099-023

Novartis Investigative Site, Lisbon

1400-038

Novartis Investigative Site, Lisbon

4200-072

Novartis Investigative Site, Porto

812 50

Novartis Investigative Site, Bratislava

041 91

Novartis Investigative Site, Košice

06080

Novartis Investigative Site, Badajoz

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY